Anti-VEGF Video Perspectives

Healio spoke with Rishi P. Singh, MD, staff surgeon at Cleveland Clinic Cole Eye Institute, associate professor of ophthalmology at Lerner College of Medicine and Healio/OSN Board Member, about recent advances in therapy have been focused on building a better anti-VEGF inhibitor, such as products that will have longer-acting suppression and new mechanisms of action to inhibit other pathways in the first video of this series.

Healio spoke with Rishi P. Singh, MD, staff surgeon at Cleveland Clinic Cole Eye Institute, associate professor of ophthalmology at Lerner College of Medicine and Healio/OSN Board Member, about highlights from the ARVO and ASRS 2020 virtual meeting, including promising safety data on port delivery system.

Healio spoke with Rishi P. Singh, MD, staff surgeon at Cleveland Clinic Cole Eye Institute, associate professor of ophthalmology at Lerner College of Medicine and Healio/OSN Board Member, about what he’s looking forward to at AAO 2020, such as 10-year data from the Age-related Eye Disease Study (AREDS) 2 trial on dry AMD, important long-term data from the Protocol V study, data on newer molecules and more.

Healio spoke with Rishi P. Singh, MD, staff surgeon at Cleveland Clinic Cole Eye Institute, associate professor of ophthalmology at Lerner College of Medicine and Healio/OSN Board Member, about how he picks anti-VEGF regimens for his patients using an evidence-based approach.

Healio spoke with Rishi P. Singh, MD, staff surgeon at Cleveland Clinic Cole Eye Institute, associate professor of ophthalmology at Lerner College of Medicine and Healio/OSN Board Member, about greatest areas of unmet need in anti-VEGF treatment for neovascular AMD and other retinal vascular diseases, including a need to better monitor patients remotely to get a longitudinal view of what’s happening with patients and the need for durable treatment options, and the need for more insight into prognostication.